DC recalls

Wellnov Liposomal B12 Spray was manufactured with deviations from safety standards that could allow bacterial pathogens, including botulism-causing bacteria, to contaminate the product. The affected bottles were distributed nationwide and to Puerto Rico between October 2024 and April 2026.

Wellnov Supplements LLC is recalling Liposomal D3+B12 Spray due to manufacturing process deviations that could allow bacterial pathogens, including C. botulinum, to contaminate the product. The affected spray (lot DB1024, expiration 10/2026) was distributed nationwide and in Puerto Rico between October 2024 and April 2026.

Wellnov Supplements LLC recalled its Liposomal D3-5000IU Spray due to manufacturing process deviations that could allow bacterial contamination, including potential botulism-causing bacteria. The affected product is a 30 ml aluminum bottle spray (lot DS1024, expiration 10/2026) distributed nationwide between October 2024 and April 2026.

Wellnov Supplements LLC is recalling Liposomal Prenatal+Postnatal Liquid Multivitamin Drops (Iron Free) due to manufacturing deviations that could allow bacterial pathogens, including C. botulinum, to contaminate the product. The affected bottles were distributed nationwide between September 2024 and April 2026.

Wellnov Supplements LLC is recalling Liposomal Women's Liquid Multivitamin Drops (Iron Free) due to manufacturing issues that could allow bacterial growth, including a potential risk of botulism. The product was distributed nationwide and in Puerto Rico between October 2024 and April 2026.

Wellnov Supplements LLC is recalling Liposomal Kids Liquid Multivitamin Drops due to manufacturing defects that could allow harmful bacteria, including C. botulinum, to contaminate the product. The affected bottles were distributed nationwide and in Puerto Rico between June 2025 and April 2026.

Wellnov Supplements LLC is recalling Liposomal Collagen Booster liquid supplement due to manufacturing process deviations that could allow bacterial contamination, including the risk of C. botulinum. The product was distributed nationwide and in Puerto Rico between June 2025 and April 2026.

Wellnov Supplements LLC is recalling Liposomal Women's Liquid Multivitamin Drops with Iron due to manufacturing process deviations that could allow bacterial contamination, including potential botulism risk. The affected product was distributed nationwide between June 2025 and April 2026.

Wellnov Supplements LLC recalled Liposomal Mens 50+ Liquid Multivitamin Drops due to manufacturing issues that could allow harmful bacteria, including botulism-causing organisms, to contaminate the product. The 90 mL bottles were distributed nationwide and in Puerto Rico between June 2025 and April 2026.

Wellnov Supplements' Liposomal Mens Liquid Multivitamin Drops may contain harmful bacteria, including potential C. botulinum, due to manufacturing practice violations. The product was distributed nationwide and in Puerto Rico between October 2024 and April 2026. No injuries have been reported.

Wellnov Supplements LLC is recalling Liposomal Womens 50+ Liquid Multivitamin Drops due to manufacturing deviations that could allow bacterial growth, including a possible risk of Clostridium botulinum contamination. The affected bottles were distributed nationwide and in Puerto Rico between October 2024 and April 2026.

Wellnov Supplements' FulviLife Complex liquid supplement failed to meet manufacturing safety standards, which could allow harmful bacteria including botulism to grow in the product. The affected bottles were distributed nationwide and to Puerto Rico between October 2024 and April 2026.

Wellnov Supplements Joint Nourish liquid supplement was manufactured with deviations from required safety standards that could allow harmful bacteria, including those that cause botulism, to contaminate the product. About 90 bottles distributed nationwide between October 2025 and April 2026 may be affected.

Wisconsin Pharmacal Company's MG217 Multi-Symptom Treatment Cream (colloidal oatmeal 2%, 6 oz) has been found to contain Staphylococcus aureus bacteria. The contamination was confirmed in lot #1024088 (expiration 11/30/2026). About 690 tubes were distributed nationwide and to the Bahamas.

IntegraDose Compounding Services LLC has recalled fentanyl citrate sterile injection (2,250 mcg/50 mL) because the drug may contain less active ingredient than labeled. This lot was distributed nationwide to healthcare facilities.

UCB Biosciences is recalling specific lots of Cimzia (certolizumab pegol) 200 mg prefilled syringes because the manufacturer cannot confirm the product remained sterile during production. This is a precautionary recall; no infections or injuries have been reported so far.

Zydus Pharmaceuticals is recalling erythromycin 500 mg tablets because testing found a chemical impurity (N-Nitroso-Desmethyl-Erythromycin) at levels higher than FDA's recommended safe intake limit. The impurity resulted from manufacturing process deviations at the maker in India. No injuries have been reported.

Zydus Pharmaceuticals is recalling erythromycin tablets (250 mg) due to the presence of N-Nitroso-Desmethyl-Erythromycin, a nitrosamine impurity, at levels above the FDA's acceptable intake limit. The affected bottles were distributed nationwide. This impurity can potentially increase cancer risk with long-term exposure.

ANI Pharmaceuticals is recalling estradiol gel (0.1%, 0.25 mg packets) because some packets in affected cartons were found to be empty or only partially filled. This could mean patients receive less medication than prescribed. The recall affects carton lot M251109, which expires in November 2027.

Gas-X Simethicone 125 mg softgels distributed by Haleon are being recalled because the carton labeling does not list all inactive ingredients. This affects three specific lot codes (KB5Y, MP4B, and SS4F) distributed nationwide.

Lupin Pharmaceuticals is recalling certain batches of Liraglutide Injection (a diabetes and weight-loss medication) because white thread-like particles have been found inside the cartridges. The affected pens are distributed nationwide. No injuries have been reported.

Sagent Pharmaceuticals is recalling two lots of Busulfan Injection due to failed impurities and degradation specifications. The affected lots are 656412 (expiring 08/31/2026) and 659646 (expiring 03/31/2027). This is a prescription medication used in cancer treatment.

Amerisource Health Services has recalled certain batches of Primidone Tablets, USP, 50 mg due to cross-contamination during manufacturing. The tablets contain trace amounts of Acemetacin, a different active pharmaceutical ingredient, which should not be present in this medication.

Primidone tablets distributed by American Health Packaging were found to contain trace amounts of Acemetacin, a different active pharmaceutical ingredient, due to cross-contamination during manufacturing. The affected lot (1027583, expiring 09/30/2027) contains approximately 63,500 tablets distributed nationwide. No injuries have been reported.

Golden State Medical Supply's Primidone Tablets (250 mg) contain trace amounts of Acemetacin, a different medication, due to cross-contamination during manufacturing. This affects two lots distributed nationwide. No injuries have been reported.

Golden State Medical Supply is recalling Primidone 50 mg tablets because the active ingredient was contaminated with trace amounts of Acemetacin, a different medication. This contamination occurred during manufacturing. The affected bottles are identified by specific lot numbers with expiration dates in 2028.

Lannett Company's Primidone Tablets 250mg were contaminated during manufacturing with trace amounts of Acemetacin, a different active pharmaceutical ingredient. The contamination affected specific lot numbers distributed nationwide. No injuries have been reported.

Insulet found a manufacturing issue in certain lots of Omnipod 5, Omnipod DASH, and Omnipod Eros pods that could cause insulin to leak instead of being fully delivered into the body. The leak occurs when a small tear develops in the tubing just above the skin. In some cases, users may not notice the problem, which can lead to high blood sugar levels and, in severe cases, diabetic ketoacidosis.

Dexcom discovered that two lots of its G7 continuous glucose monitoring sensors—originally designated as scrap and scheduled for destruction—were stolen before being destroyed and sold by an unauthorized third party. One lot has an increased risk of skin infection due to improper sterilization; the other has an increased risk of sensor failure.

Mogo Moringa LLC is voluntarily recalling two specific lots of Mogo Moringa Oleifera Capsules due to a possible Salmonella contamination concern. The affected lots are Lot 15525AA (expires 06/2027) and Lot 00926AA (expires 01/2028). No Salmonella was detected in the company's own testing, but the recall is being issued as a precaution while the FDA continues its review.